ICU Medical, Inc. Hits New 52-Week High of $167.99

ICU Medical, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 167.99 on July 28, 2026. This achievement underscores the company's strong performance over the past year, with a remarkable increase of 49.81%, significantly outpacing the S&P 500's growth of 16.26% during the same period. The company's market capitalization stands at USD 3,066 million, reflecting its position within the small-cap segment. ICU Medical's price-to-earnings (P/E) ratio is currently at 46.00, indicating investor sentiment regarding its earnings potential. Additionally, the company maintains a debt-to-equity ratio of 0.47, suggesting a relatively conservative approach to leveraging. Despite not offering a dividend yield, ICU Medical's return on equity is recorded at 3.14%, and its price-to-book ratio is 1.44. The stock's previous 52-week low was USD 107, highlighting the significant upward movement in its valuation. This new high marks a pivotal moment for ICU Medical, reflecting its ongoing performance in the competitive pharmaceuticals and biotechnology landscape.